Yesterday, Optimi Health announced an important MDMA and psilocybin distribution agreement for the psychedelic sector.
Our new long-term relationship with Mind Medicine Australia positions Optimi as the primary supplier to Australia’s newly regulated psychedelic market.
From day one, our goal has been to become the best end-to-end psychedelics manufacturer and formulator in the world. Over the last three years, we have drawn from our past experiences in our other successful business ventures to position Optimi as a leader in this emerging market. We will continue to apply that same work ethic in the years to come.
We’ve demonstrated our commitment to this objective by constructing the largest dedicated GMP psychedelics facility in the space, hiring top analytical chemists and scientists, and surrounding ourselves with an incredibly talented operations and management team that cares passionately about helping people.
Optimi is not reliant on contract manufacturing to source and supply any of its products. We are the manufacturer. Our business model of being a true end-to-end producer puts us in the position to lead the supply of medical-grade psychedelics throughout regulated jurisdictions. This advantage was instrumental in helping us build our network in the Australian psychedelics market.
Our signed Purchase Orders with Mind Medicine Australia will ensure that patients with treatment resistant post-traumatic stress disorder (PTSD) have access to medical grade GMP MDMA (using Optimi Health’s MDMA formulation, OPTI-MHCL) and patients with treatment resistant depression have access to GMP encapsulated psilocybin as part of therapy through their authorized treating psychiatrists when rescheduling becomes effective on July 1, 2023.
From the first conversation we had with Mind Medicine Australia Chair, Peter Hunt, to the signing of the Purchase Order, we made it our mission to “fulfill a higher humanitarian purpose,” which meant providing a scalable and affordable product that would be accessible to all Australians.
As we enter the next phase of our existence, we would like to thank our shareholders for making this development possible. It is because of your patience, support, and belief from the very beginning, that we are now able to deliver on the promise of psychedelic medicine.
As new jurisdictions open and we further expand the scope of our production and distribution to meet demand, our position as a true end-to-end supplier will continue to ensure the same competitive advantage that has allowed us to secure this immediate primacy in the Australian market.
Optimi’s founders have been committed to heading and financing our operations. This remains the case as our journey to becoming the leading global distributor of GMP psychedelic compounds is well and truly underway. Australia was the first step. It will not be the last.
We look forward to sharing more exciting news with you soon.
Dane, JJ, Bryan & Jacob